Atlanta Braves outfielder Jurickson Profar faces a 162-game suspension after testing positive for a performance-enhancing drug (PED) for the second time in his career. The suspension will cost him his $15 million salary and eligibility for the postseason and World Baseball Classic.
Key Takeaways
Atlanta Braves outfielder Jurickson Profar faces a 162-game suspension after testing positive for a performance-enhancing drug (PED) for the second time in his career. The suspension will cost him his $15 million salary and eligibility for the postseason and World Baseball Classic.
- Atlanta Braves' Jurickson Profar is facing a 162-game suspension for a second PED violation.
- Profar tested positive for Chorionic Gonadotrophin (hCG), which aids in testosterone production.
- The suspension will cost him his $15 million salary and eligibility for the postseason and World Baseball Classic.
- This is Profar's second PED-related suspension, having previously served an 80-game ban last year.
According to multiple reports, Profar tested positive for Chorionic Gonadotrophin (hCG), a hormone that aids in testosterone production. This is Profar's second PED-related suspension, having previously served an 80-game ban last year after testing positive for the same substance.
Profar will forfeit his $15 million salary and be ineligible for the postseason as well as the World Baseball Classic, where he was set to play for the Netherlands. He is expected to appeal the suspension through a grievance filed by the players' association.
The Braves released a statement expressing their disappointment, emphasizing that they fully support MLB's drug prevention and treatment program. The team had targeted Profar as its primary designated hitter following the offseason signing of left fielder Mike Yastrzemski to a two-year, $23 million deal.
Profar is the seventh player suspended 162 games for a second PED infraction since MLB increased penalties over a decade ago. He becomes the latest in a string of players facing significant suspensions this year due to positive drug tests.
How this summary was created
This summary synthesizes reporting from 3 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.